Please assess the completion status of the following clinical trial:

Trial Title: To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of active ME secondary to any causes (for adult patients: except diabetic macular edema (DME), age-related macular degeneration (AMD) and retinal vein occlusion (RVO));~* BCVA must be between ≥ 24 and ≤ 83 letters;~* Visual loss should be mainly due to the presence of any eligible types of ME.~Exclusion Criteria:~* Women of child-bearing potential,~* Active malignancies;~* History of stroke less than 6 months prior to screening;~* Uncontrolled systemic inflammation or infection, related directly to the underlying causal disease of ME;~* Active diabetic retinopathy, active ocular/periocular infectious disease or active severe intra-ocular inflammation;~* Any type of advanced, severe or unstable ocular disease or its reatment;~* ME with a high likelihood of spontaneous resolution.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
- Sham control (Type: SHAM_COMPARATOR): Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).